부산대학교 도서관

Background: Major Depressive Episodes (MDEs) may characterise many psychiatric disorders.Its pharmacotherapy is laid with unmet needs, rendering the testing of new drugs necessary.Objective: To compare the effects of vortioxetine with those of other antidepressants (OADs) in a1-year naturalistic setting.Methods: We included 126 adult patients with anMDE in the course of major depressive (MDD),bipolar (BD), or schizophrenia spectrum disorders (SSOPDs), with or without substance use disorder(SUD), who received 5-20 mg/day oral vortioxetine, and compared them with 100 patients receivingOADs at baseline and after 1, 3, 8, and 12 months on their scores on the MADRS, the CGIS,the 24-item BPRS, the YMRS, the Hamilton Anxiety Rating Scale, a Visual Analogue Scale forcraving, the Columbia-Suicide Severity Rating Scale, and the WHOQOL-BREF.Results: Patients on vortioxetine improved similarly to those on OADs on all measures, independentlyfrom having or not a comorbid SUD. However, they improved with time better than theirOADcounterparts if affected by BD or SSOPDs, but not MDD, on the CGI-S, BPRS depression,anxiety, and manic symptoms. SUD hampered the response of anxiety to treatment. Men improvedon depression with time better than women.Conclusion: MDEs responded to vortioxetine similarly to OADs by improving in depression, generalpsychopathology, anxiety, suicidal thinking, and quality-of-life, independently from SUD comorbidity.MDEs of patients with BD or SSOPDs on vortioxetine responded better than that of patientson OADs. Clinical Trial Registration No. 17354N.